Last updated: July 28, 2026
Phenprocoumon (CAS 1047-70-7) is an oral vitamin K antagonist (VKA) anticoagulant used for long-term prevention of thromboembolic events. Public, drug-development “clinical trials update” visibility is limited because the product is established and often marketed under national registrations rather than as a repeatedly re-evaluated, modern NDA/ANDA development program. Business-relevant activity therefore concentrates on (1) label updates, (2) safety monitoring and real-world effectiveness/bleeding data, and (3) competitive access through generic and regional brand portfolios rather than new Phase 3 pivotal studies.
What clinical trials involve phenprocoumon and what is the latest update?
Latest clinical-trials signal: no clearly attributable, high-profile Phase 3 or new investigational pivotal program tied to phenprocoumon in major registries. The contemporary evidence base largely comes from real-world registry studies, comparative anticoagulation studies, and pharmacovigilance or dosing-management research rather than new late-stage development.
Where does phenprocoumon research activity typically show up?
Clinical work on phenprocoumon tends to fall into these categories:
- Dosing management and INR control (quality-of-control metrics, time-in-therapeutic range, bridging behavior)
- Bleeding risk stratification (elderly, renal impairment, drug-drug interaction risk)
- Pharmacogenetics and monitoring strategies (where VKORC1/CYP-related variation is discussed across VKAs)
- Comparative effectiveness studies versus DOACs in indicated populations (AF, VTE, mechanical valves depending on label context)
Trials vs. registries: what to treat as “update”
For phenprocoumon, the most decision-relevant “update” for regulators, payers, and sponsors is usually not a new Phase 3 readout, but changes in:
- observed bleeding rates under contemporary management
- persistence/adherence under INR monitoring models
- guideline and consensus positioning (where VKAs keep roles where DOACs are less preferred, such as specific high-risk valve populations in many jurisdictions)
How big is the phenprocoumon market and what drives demand?
Phenprocoumon’s market is driven by continued VKA utilization for:
- long-term oral anticoagulation where DOACs are less used (often for populations where clinicians prefer VKAs, such as selected mechanical heart valve cohorts depending on national practice)
- patients stable on phenprocoumon within INR-management systems
- healthcare settings with established INR monitoring infrastructure
Market composition: national branded portfolios and generics
Phenprocoumon is typically not a single global brand story. Commercial exposure is usually a function of:
- local brand availability and pricing controls
- generic substitution rules (tender dynamics, pharmacist substitution in some markets)
- therapeutic competition from DOACs, which has pressured VKA share growth in many European markets
Key demand drivers (commercial)
- INR-management capacity: stable clinic workflows support VKA continuation and switching avoidance.
- Physician preference and guideline interpretation: practice patterns persist.
- DOAC reimbursement/coverage: where DOAC uptake is high, phenprocoumon share tends to shrink.
- Drug-drug interaction burden: in medically complex patients, clinicians may prefer or continue a known VKA regimen.
What is the competitive landscape for phenprocoumon versus warfarin and DOACs?
Phenprocoumon vs warfarin (VKA class competition)
Both are VKAs. Competitive differences typically reflect:
- availability and clinician familiarity by region
- product formulation and dosing convenience (tablet strength landscape)
- local prescribing habits and therapeutic monitoring culture
Phenprocoumon vs DOACs (primary market share pressure)
DOAC adoption has been a structural headwind across many European markets. The gap phenprocoumon occupies tends to be where clinicians:
- prefer VKAs for certain high-risk indications
- manage patients who are stable on phenprocoumon and avoid switching risks
- face DOAC contraindications or payer constraints
What is the patent and regulatory exclusivity status for phenprocoumon?
Phenprocoumon is an old, off-patent active ingredient in most jurisdictions, so market exclusivity is typically not anchored to primary API composition-of-matter patents for current products. Current market access is generally governed by:
- local formulation and manufacturing authorizations
- brand-specific data protection periods, where applicable
- generic market authorization pathways and product-specific regulatory dossiers
Where can “exclusivity” still matter in practice?
Even with a mature API, exclusivity can persist in limited forms:
- brand product-specific regulatory exclusivity in certain countries
- line extensions (new strengths, new formulation type, improved release profile), if any were registered recently in a particular country
- data exclusivity for process changes (rare at scale for an established molecule)
When does phenprocoumon lose exclusivity and how does this affect generic entry risk?
Because the API is mature, generic entry risk is generally low from an API exclusivity standpoint. The practical risk for new entrants is not “waiting out patent expiry,” but:
- regulatory approval timelines in each target country
- procurement tender timing and reimbursement status
- ability to compete on price and supply reliability
- switching friction with entrenched INR clinics
What Orange Book status exists for phenprocoumon, and what does it imply for US generics?
Phenprocoumon is not a US-centric development target and is not typically analyzed through the US Orange Book in the way modern NDA/ANDA products are. For business planning, this means:
- US filing and market entry usually depend on whether a marketed product exists and what the pathway is (and not on a clean Orange Book exclusivity readout)
- most competitive exposure is European rather than US-led
(If you need an Orange Book listing-by-listing map, it must be derived from actual Orange Book records for the specific marketed phenprocoumon products.)
What FDA regulatory pathway exists for phenprocoumon and what is the commercialization constraint?
There is no broad contemporary FDA development narrative for phenprocoumon comparable to modern anticoagulant launches. Commercialization constraints, where relevant, are mainly:
- product availability and regulatory approvals in a given country
- labeling alignment and clinical guidance uptake
- competition from DOACs with stronger marketing and guideline momentum
How many generics and authorized products exist for phenprocoumon and where are they sold?
A complete count requires country-by-country authorization data. Practically, the market is characterized by:
- multiple authorized generics across European markets
- branded historical products in some regions
- substitution governed by national rules and tender dynamics
What formulations are protected for phenprocoumon (strengths, dosage forms, and release characteristics)?
For established VKAs, formulation protection is usually limited. The recurring business question is whether any modern product differentiations exist:
- tablet strength availability and stability profile
- excipient differences that alter dissolution
- packaging and handling features
In many markets, generics match the reference formulation sufficiently for regulatory approval, reducing the value of formulation-only IP as an entry barrier.
What patent estate strength exists for phenprocoumon and where does it matter in litigation?
Given the molecule age, litigation risk is usually not about base phenprocoumon composition-of-matter patents. Where disputes occur, they are more likely to relate to:
- product-specific regulatory dossiers
- local IP around a particular marketed brand’s dossier history
- method-of-use claims, if any were pursued in specific jurisdictions
For business planning, the litigation landscape is more likely to be about regional brand/generic disputes than global, molecule-level exclusivity.
Market projection for phenprocoumon: 3-year and 5-year outlook
Base-case market dynamics (structural)
- DOAC share gains continue to compress VKA growth.
- VKA persistence remains meaningful in patients stable on therapy and in specific high-risk cohorts, supporting a stable-to-declining but not collapsing demand curve.
- Price pressure from generics limits revenue growth even if volume holds.
Projection framing for revenue and volume
Without country-level sales baselines, the most decision-useful projection is directional:
3-year outlook
- Volume: likely flat to mildly down, depending on national DOAC uptake rates.
- Value: down modestly due to price competition and tender dynamics.
- Competitive impact: continued erosion from DOAC-led prescribing.
5-year outlook
- Volume: mild decline expected in most regions with high DOAC penetration.
- Value: more pronounced decline than volume due to erosion of branded premium and sustained generic price pressure.
- Strategic implication: survival is driven by supply contracts, formularies, and stable INR clinic throughput.
Commercial strategy implications for sponsors and investors
Where phenprocoumon still wins
- healthcare systems with entrenched INR monitoring pathways
- patient segments where switching away from phenprocoumon is clinically or administratively discouraged
- markets where DOAC uptake is slower or reimbursement restricts DOAC use
Where phenprocoumon loses
- high-uptake DOAC systems
- settings emphasizing simplified anticoagulation regimens
- tender environments that favor lowest-cost alternatives with broader guideline alignment
Key data table: business checklist for phenprocoumon market entry
| Category |
What to validate |
Business relevance |
| Regulatory status |
Country-specific marketing authorizations, strengths, and substitutions |
Determines launch feasibility and timelines |
| Product competition |
Local brand vs generic mix and tender patterns |
Sets pricing ceiling |
| Patient switching |
Evidence of persistence on phenprocoumon in real-world settings |
Impacts volume stability |
| DOAC substitution |
DOAC reimbursement and uptake trajectory |
Defines structural demand pressure |
| Safety operations |
Bleeding/vigilance experience under local pharmacovigilance rules |
Impacts payer confidence and uptake |
| Supply chain |
API and tablet manufacturing capacity |
Avoids lost tender awards |
Key Takeaways
- Phenprocoumon’s commercial story is dominated by mature VKA market dynamics and DOAC-led share pressure, not new late-stage development.
- “Clinical trials update” activity is typically real-world and dosing-management oriented rather than pivotal Phase 3 breakthroughs.
- Exclusivity is generally not a main barrier because the API is mature; competitive entry is more constrained by regulatory authorization, tender pricing, and switching friction.
- Market outlook is directionally stable-to-declining: volume holds better than revenue under generic price competition.
FAQs
- How does phenprocoumon’s bleeding risk compare with DOACs in real-world anticoagulation?
- What INR control metrics best predict outcomes for phenprocoumon-treated patients?
- Which patient subgroups are more likely to stay on phenprocoumon instead of switching to DOACs?
- What country-level regulatory factors most affect phenprocoumon generic approvals and pricing?
- How do tender and reimbursement policies influence phenprocoumon market share versus competing VKAs?
References
- European Medicines Agency (EMA). EPAR and product information documents for vitamin K antagonists where applicable.
- FDA. Orange Book database (product listings, if applicable to phenprocoumon marketed products).
- ClinicalTrials.gov. Phenprocoumon-related entries (search results by condition and study type).
- PubMed. Real-world observational studies comparing VKAs and DOACs in AF/VTE populations where phenprocoumon appears in cohorts.
